TY - JOUR
T1 - Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
AU - Chaisson, Richard E.
AU - Clermont, H. Camil
AU - Holt, Elizabeth A
AU - Cantave, Mireille
AU - Johnson, Michael P.
AU - Atkinson, Joan
AU - Davis, Homer
AU - Boulos, Reginald
AU - Quinn, Thomas C.
AU - Halsey, Neal A.
AU - Desormeaux, Julio
AU - Joseph, Henri
AU - Buteau, Josianne
AU - LaMothe, Franz
AU - Elie, Robert
AU - Charache, Patricia
AU - Siddiqi, Salman
AU - Eaton, Abigail
AU - Clements, Audrey
PY - 1996
Y1 - 1996
N2 - We enrolled 427 consecutive patients with tuberculosis diagnosed in Cite Soleil, Haiti in a trial of short-course intermittent therapy. All patients received supervised therapy with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, followed by isoniazid and rifampin thrice weekly for 18 wk. At entry, the 177 human immunodeficiency virus (HIV)- infected patients (42%) were found significantly more likely to have extrapulmonary tuberculosis and negative tuberculin skin tests (p < 0.05). Treatment was well tolerated by both groups of patients, and adherence to the treatment regimen was over 90%. Among patients with pulmonary or intrathoracic tuberculosis, 9% of HIV-seropositive and 1% of HIV-seronegative patients died during therapy (p < 0.001), whereas 81% and 87%, respectively, of those in the two groups were cured. Relapses occurred in 5.4% of HIV- seropositive and 2.8% of HIV-seronegative patients who completed treatment (p = 0.36). Survival after tuberculosis was poorer in HIV-seropositive patients, whose probability of dying was 33% at 18 mo after diagnosis as compared with 3% for HIV-seronegative patients (p < 0.001). HIV-seropositive patients who died had significantly lower median CD4 lymphocyte counts than did HIV- seropositive patients who survived (p < 0.001). Treatment of tuberculosis with short-course, thrice-weekly, supervised therapy in the setting of a developing country is highly efficacious in both HIV-seropositive and - seronegative patients.
AB - We enrolled 427 consecutive patients with tuberculosis diagnosed in Cite Soleil, Haiti in a trial of short-course intermittent therapy. All patients received supervised therapy with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, followed by isoniazid and rifampin thrice weekly for 18 wk. At entry, the 177 human immunodeficiency virus (HIV)- infected patients (42%) were found significantly more likely to have extrapulmonary tuberculosis and negative tuberculin skin tests (p < 0.05). Treatment was well tolerated by both groups of patients, and adherence to the treatment regimen was over 90%. Among patients with pulmonary or intrathoracic tuberculosis, 9% of HIV-seropositive and 1% of HIV-seronegative patients died during therapy (p < 0.001), whereas 81% and 87%, respectively, of those in the two groups were cured. Relapses occurred in 5.4% of HIV- seropositive and 2.8% of HIV-seronegative patients who completed treatment (p = 0.36). Survival after tuberculosis was poorer in HIV-seropositive patients, whose probability of dying was 33% at 18 mo after diagnosis as compared with 3% for HIV-seronegative patients (p < 0.001). HIV-seropositive patients who died had significantly lower median CD4 lymphocyte counts than did HIV- seropositive patients who survived (p < 0.001). Treatment of tuberculosis with short-course, thrice-weekly, supervised therapy in the setting of a developing country is highly efficacious in both HIV-seropositive and - seronegative patients.
UR - http://www.scopus.com/inward/record.url?scp=10244242548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10244242548&partnerID=8YFLogxK
U2 - 10.1164/ajrccm.154.4.8887603
DO - 10.1164/ajrccm.154.4.8887603
M3 - Article
C2 - 8887603
AN - SCOPUS:10244242548
VL - 154
SP - 1034
EP - 1038
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 4 I
ER -